Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

University Hospital, Bordeaux50 enrolled

Overview

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown. The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

SINGLE

Enrollment

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged more than 40 yr * Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery. * COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines. * Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex. * with a written informed consent Exclusion Criteria: * Subject without any social security or health insurance * Asthma, lung fibrosis or idiopathic pulmonary hypertension * Chronic viral infections (hepatitis, HIV) * Pregnant woman or breastfeeding * Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.

Outcomes

Primary Outcomes

Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects.

Time frame: Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)

Secondary Outcomes

Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II

Time frame: Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)

Correlation between lung attenuation and the number of fibrocytes

Time frame: Assessed one year after inclusion visit (i.e. surgery date =Day 0)

Correlation between plethysmography and the number of fibrocytes.

Time frame: Assessed one year after inclusion visit (i.e. surgery date = Day 0)